Antiretroviral activity of metal-chelating HIV-1 integrase inhibitors

European Journal of Medicinal Chemistry

Volumn 83, Issue , 2014, Pages 594-600

  Carcelli, Mauro ^a   Rogolino, Dominga ^a   Sechi, Mario ^b   Rispoli, Gabriele ^a   Fisicaro, Emilia ^a   Compari, Carlotta ^a   Grandi, Nicole ^c   Corona, Angela ^c   Tramontano, Enzo ^c   Pannecouque, Christophe ^d   Naesens, Lieve ^d  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiviral agents; Dual inhibitors; HIV 1 integrase inhibitors; HIV 1 RNase H inhibitors; Metal complexes

Indexed keywords

AMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHELATING AGENT; COORDINATION COMPOUND; DIDANOSINE; ELVITEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; METAL COMPLEX; NEVIRAPINE; RALTEGRAVIR; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; ZALCITABINE; ZIDOVUDINE; METAL CHELATE; LIGAND;

ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; CELL VIABILITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN IIIB); HUMAN IMMUNODEFICIENCY VIRUS 2 (STRAIN ROD); IC 50; ISOTHERMAL TITRATION CALORIMETRY; NONHUMAN; THERMODYNAMICS; X RAY DIFFRACTION; ABSORPTION; ANTIRETROVIRAL ACTIVITY; CELL TRANSPORT; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG UPTAKE; ENTHALPY; ENTROPY; HYDROGEN BOND; IC50; IN VITRO STUDY; IONIC STRENGTH; LIPOPHILICITY; PHYSICAL CHEMISTRY; POTENTIOMETRY; STOICHIOMETRY; CELL LINE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 2; METABOLISM;

ANTI-HIV AGENTS; CELL LINE; CHELATING AGENTS; COORDINATION COMPLEXES; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HIV-2; INHIBITORY CONCENTRATION 50; LIGANDS; THERMODYNAMICS;

EID: 84903761392     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.06.055     Document Type: Article

References (44)

1. N.P. Barry, and P.J. Sadler Exploration of the medical periodic table: towards new targets Chem. Commun. 49 2013 5106 5131
2. D. Rogolino, M. Carcelli, M. Sechi, and N. Neamati Viral enzymes containing magnesium: metal binding as a successful strategy in drug design Coord. Chem. Rev. 256 2012 3063 3086
3. L. Hocharoen, and J. Cowan Metallotherapeutics: novel strategies in drug design Chemistry 15 2009 8670 8676
4. L. Ronconi, and P.J. Sadler Using coordination chemistry to design new medicines Coord. Chem. Rev. 251 2007 1633 1648
5. B. Johns, and A.C. Svolto Advances in two-metal chelation inhibitors of HIV integrase Expert Opin. Ther. Pat. 18 2008 1225 1237
6. G.N. Maertens, S. Hare, and P. Cherepanov The mechanism of retroviral integration from X-ray structures of its key intermediates Nature 468 2010 326 329
7. E. Khan, J.P. Mack, R. Katz, J. Kulkosky, and M. Skalka Retroviral integrase domains: DNA binding and the recognition of LTR sequences Nucl. Acids Res. 19 1991 851 860 (Pubitemid 21913161)
8. N. Neamati HIV-1 Integrase: Mechanism of Action and Inhibitor Design 2011 John Wiley & Sons
9. T. Steitz, and J. Steitz A general two-metal-ion mechanism for catalytic RNA PNAS 90 1993 6498 6502 (Pubitemid 23207240)
10. C. Hicks, and R.M. Gulick Raltegravir: the first HIV type 1 integrase inhibitor Clin. Infect. Dis. 48 2009 931 939
11. V. Summa, A. Petrocchi, F. Bonelli, B. Crescenzi, M. Donghi, M. Ferrara, F. Fiore, C. Gardelli, O. Gonzalez Paz, D.J. Hazuda, P. Jones, O. Kinzel, R. Laufer, E. Monteagudo, E. Muraglia, E. Nizi, F. Orvieto, P. Pace, G. Pescatore, R. Scarpelli, K. Stillmock, M.V. Witmer, and M. Rowley Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection J. Med. Chem. 51 2008 5843 5855
12. M. Sato, T. Motomura, H. Aramaki, T. Matsuda, M. Yamashita, Y. Ito, H. Kawakami, Y. Matsuzaki, W. Watanabe, K. Yamataka, S. Ikeda, E. Kodama, M. Matsuoka, and H. Shinkai Novel HIV-1 integrase inhibitors derived from quinolone antibiotics J. Med. Chem. 49 2006 1506 1508 (Pubitemid 43376497)
13. T. Kawasuji, B. Johns, H. Yoshida, J.G. Weatherhead, T. Akiyama, T. Taishi, Y. Taoda, M. Mikamiyama-Iwata, H. Murai, R. Kiyama, M. Fuji, N. Tanimoto, T. Yoshinaga, T. Seki, M. Kobayashi, A. Sato, E.P. Garvey, and T. Fujiwara Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles J. Med. Chem. 56 2013 1124 1135
14. B.A. Johns, T. Kawasuji, J.G. Weatherhead, T. Taishi, D.P. Temelkoff, H. Yoshida, T. Akiyama, Y. Taoda, H. Murai, R. Kiyama, M. Fuji, N. Tanimoto, J. Jeffrey, S.A. Foster, T. Yoshinaga, T. Seki, M. Kobayashi, A. Sato, M.N. Johnson, E.P. Garvey, and T. Fujiwara Carbamoyl pyridone HIV-1 integrase inhibitors. 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744) J. Med. Chem. 56 2013 5901 5916
15. S.L. Karmon, and M. Markowitz Next-generation integrase inhibitors: where to after raltegravir? Drugs 73 2013 213 228
16. R. Dayam, R. Gundla, L.Q. Al-Mawsawi, and N. Neamati HIV-1 integrase inhibitors: 2005-2006 update Med. Res. Rev. 28 2008 118 154 (Pubitemid 350274962)
17. K.D. Beare, M.J. Coster, and P.J. Rutledge Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond Curr. Med. Chem. 19 2012 1177 1192
18. E.A. Semenova, and C. Marchand HIV-1 integrase inhibitors: update and perspectives Adv. Pharm. 56 2008 199 228
19. E. Zeinalipour-Loizidou, C. Nicolaou, A. Nicolaides, and L.G. Kostrikis HIV-1 integrase: from biology to chemotherapeutics Curr. Hiv. Res. 5 2007 365 388 (Pubitemid 47044734)
20. A. Agrawal, J. DeSoto, J.L. Fullagar, K. Maddali, S. Rostami, D.D. Richman, Y. Pommier, and S.M. Cohen Probing chelation motifs in HIV integrase inhibitors PNAS 109 2012 2251 2256
21. T. Kawasuji, B. Johns, H. Yoshida, T. Taishi, Y. Taoda, H. Murai, R. Kiyama, M. Fuji, T. Yoshinaga, T. Seki, M. Kobayashi, A. Sato, and T. Fujiwara Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore J. Med. Chem. 55 2012 8735 8744
22. M. Sechi, A. Bacchi, M. Carcelli, C. Compari, E. Duce, E. Fisicaro, D. Rogolino, P. Gates, M. Derudas, L.Q. Al-Mawsawi, and N. Neamati From ligand to complexes: inhibition of human immunodeficiency virus type 1 integrase by β-diketo acid metal complexes J. Med. Chem. 49 2006 4248 4260 (Pubitemid 44036668)
23. A. Bacchi, M. Biemmi, M. Carcelli, F. Carta, C. Compari, E. Fisicaro, D. Rogolino, M. Sechi, M. Sippel, C. Sotriffer, T.W. Sanchez, and N. Neamati From ligand to complexes. Part 2. Remarks on human immunodeficiency virus type 1 integrase inhibition by β-diketo acid metal complexes J. Med. Chem. 51 2008 7253 7264
24. A. Bacchi, M. Carcelli, C. Compari, E. Fisicaro, N. Pala, G. Rispoli, D. Rogolino, T.W. Sanchez, M. Sechi, V. Sinisi, and N. Neamati Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors J. Med. Chem. 54 2011 8407 8420
25. A. Bacchi, M. Carcelli, C. Compari, E. Fisicaro, N. Pala, G. Rispoli, D. Rogolino, T.W. Sanchez, M. Sechi, and N. Neamati HIV-1 IN strand-tranfer chelating inhibitors: a focus on metal binding Mol. Pharm. 8 2011 507 519
26. M. Carcelli, A. Bacchi, P. Pelagatti, G. Rispoli, D. Rogolino, T.W. Sanchez, M. Sechi, and N. Neamati Ruthenium arene complexes as HIV-1 integrase strand transfer inhibitors J. Inorg. Biochem. 118 2013 74 82
27. D. Rogolino, M. Carcelli, C. Compari, L. De Luca, S. Ferro, E. Fisicaro, G. Rispoli, N. Neamati, Z. Debyser, F. Christ, and A. Chimirri Diketoacid chelating ligands as dual inhibitors of HIV-1 integration process Eur. J. Med. Chem. 78 2014 425 430
28. G. Pelosi, F. Bisceglie, F. Bignami, P. Ronzi, P. Schiavone, M.C. Re, C. Casoli, and E. Pilotti Antiretroviral activity of thiosemicarbazone metal complexes J. Med. Chem. 53 2010 8765 8769
29. S.G. Gallego, M.J. Serramía, E. Arnaiz, L. Díaz, M.A. Muñoz-Fernández, P. Gómez-Sal, M.F. Ottaviani, R. Gómez, and F.J. de la Mata Transition-metal complexes based on a sulfonate-containing N-donor ligand and their use as HIV antiviral agents Eur. J. Inorg. Chem. 2011 1657 1665
30. N.V. Loginova, T.V. Koval'chuk, G.I. Polozov, N.P. Osipovich, P.G. Rytik, I.I. Kucherov, A.A. Chernyavskaya, V.L. Sorokin, and O.I. Shadyro Synthesis, characterization, antifungal and anti-HIV activities of metal(II) complexes of 4,6-di-tert-butyl-3-[(2-hydroxyethyl)thio]benzene-1,2-diol Eur. J. Med. Chem. 43 2008 1536 1542 (Pubitemid 351885220)
31. P.N. Fonteh, F.K. Keter, and D.J. Meyer New bis(thiosemicarbazonate) gold(III) complexes inhibit HIV replication at cytostatic concentrations: potential for incorporation into virostatic cocktails J. Inorg. Biochem. 105 2011 1173 1180
32. F. Esposito, and E. Tramontano Past and future. Current drugs targeting HIV-1 integrase and reverse transcriptase-associated ribonuclease H activity: single and dual active site inhibitors Antiv. Chem. Chemother. 23 2014 129 144
33. E. Tramontano, F. Esposito, R. Badas, R. Di Santo, R. Costi, and P. La Colla 6-[1-(4-fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro Antiv. Res. 65 2005 117 124 (Pubitemid 40222288)
34. R. Costi, M. Metifiot, F. Esposito, Cuzzucoli, G. Crucitti, L. Pescatori, A. Messore, L. Scipione, S. Tortorella, L. Zinzula, E. Novellino, Y. Pommier, E. Tramontano, C. Marchand, and R. Di Santo 6-(1-Benzyl-1H-pyrrol-2-yl)-2,4- dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach J. Med. Chem. 56 2013 8588 8598
35. K. Nakamoto Infrared and Raman Spectra of Inorganic and Coordination Compounds fourth ed. 1986 Wiley New York
36. J.E. Ladbury, G. Klebe, and E. Freire Adding calorimetric data to decision making in lead discovery: a hot tip Nat. Rev. Drug Dis. 9 2010 23 27
37. E. Fisicaro, C. Compari, F. Baciottini, L. Contardi, M. Carcelli, G. Rispoli, and D. Rogolino Thermodynamics of complexes formation by ITC in methanol/water = 9/1V/V solution: a case study Thermochim. Acta 586 2014 40 44
38. P. Gans, A. Sabatini, and A. Vacca Simultaneous calculation of equilibrium constants and standard formation enthalpies from calorimetric data for systems with multiple equilibria in solution J. Sol. Chem. 37 2008 467 476
39. S. Hare, S.S. Gupta, E. Valkov, A. Engelman, and P. Cherepanov Retroviral intasome assembly and inhibition of DNA strand transfer Nature 2010 1 6
40. A.A. Johnson, C. Marchand, S.S. Patil, R. Costi, R. Di Santo, T.R. Burke Jr., and Y. Pommier Probing HIV-1 integrase inhibitor binding sites with position-specific integrase-DNA cross-linking assays Mol. Pharmacol. 71 2007 893 901 (Pubitemid 46294101)
41. S. Hare, S.J. Smith, M. Metifiot, A. Jaxa-Chamiec, Y. Pommier, S.H. Hughes, and P. Cherepanov Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572) Mol. Pharmacol. 80 2011 565 572
42. C. Pannecouque, D. Daelemans, and E. De Clercq Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later Nat. Protoc. 3 2008 427 434 (Pubitemid 351384256)
43. V. Suchaud, F. Bailly, C. Lion, E. Tramontano, F. Esposito, A. Corona, F. Christ, Z. Debyser, and P. Cotelle Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity Bioorg. Med. Chem. Lett. 22 2012 3988 3992
44. F. Esposito, C. Sanna, C. Del Vecchio, V. Cannas, A. Venditti, A. Corona, A. Bianco, A.M. Serrilli, L. Guarcini, C. Parolin, M. Ballero, and E. Tramontano Hypericum hircinum L. components as new single-molecule inhibitors of both HIV-1 reverse transcriptase-associated DNA polymerase and ribonuclease H activities Pathog. Dis. 68 2013 116 124